Facility Trends: Modularization and Single Use - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Facility Trends: Modularization and Single Use
Pharmaceutical Technology spoke with INTERPHEX 2013 conference-session presenters to gain insight on trends in facility and process design.

Pharmaceutical Technology
Volume 37, Issue 5, pp. 76-78

PharmTech: What types of modules are used in pharmaceutical production?

Sandstrom (Fluor): One common type is the building module, in which all the architectural features, equipment, and piping are preinstalled. Another commonly used concept is the tank-array module, which may include several different process-unit operations in one module. There are many other varieties of modules. In piping-specific modules, for example, you modularize just the equipment, such as a pipe rack or a large cluster of instrumentation.

PharmTech: What do you see as the future of modular manufacturing?

Sandstrom (Fluor): I see modularization as an essential component of almost all facility designs. We see it now, and we see the trend continuing in the future.

One driver is that as facilities increasingly move to more remote locations, such as in Asia or South America where local trades aren't as mature as they are in the US and Europe, there's a desire to modularize to get the hygienic components of the facility designed and fabricated in a controlled-quality location.

Almhem (Modular Partners): Modularization doesn't actually change the manufacturing itself; it's more about how you manufacture. Modules will be used as the building blocks for more and more processes simply because it's a more efficient way of building a process function, or indeed building almost anything. Nobody would consider building a software system any other way than using modules (or objects as they are called in software), for example. We will see more and more modular systems and modular pieces in pharmaceutical and biotechnology facilities and processes.

Implementing single-use systems in traditional stainless-steel facilities

PharmTech: What are some of the advantages of implementing single-use systems?

Odum (IPS): Advantages include reduction of cleaning costs via the decrease in the size or elimination of costly clean-in-place (CIP) systems because you are now getting away from fixed stainless steel equipment. Along that same line, there can be a reduction in floor space because equipment is smaller and easier to move in equipment modules. Work is being done to consider how the implementation of single-use systems can reduce the amount of classified space that you must maintain during your manufacturing operations, via validation of system closure. Perhaps the biggest advantage of single-use systems is flexibility, especially if you are looking at the issues related to process changes in early-stage development.

Many developments in the biopharmaceutical industry have added to the challenges of designing, building, and operating the traditional manufacturing facilities that we've used over the past three decades. As our insights into product requirements and product characterization increase, the critical path for the development of many new products is now shifting to the process development stage, and manufacturing timelines are being condensed. Speed and flexibility are thus becoming crucial to many of our clients.

Future manufacturing systems must be agile enough to deliver on this flexibility with regards to a wider variety of product types and in a shorter timeframe. Single-use systems can provide a means to allow for this increased flexibility and a focus on speed to market, even if you are dealing with a stainless steel-based facility.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here